Patent US4678663A successfully refreshed from Google Patents.
US4678663A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hydroquinone composition having enhanced bio-availability and percutaneous adsorption
Assignee: Neutrogena LLC
•
Filing: 1984-02-06
•
Granted: 1987-07-07
•
Expires: 2004-02-06
Abstract
Abstract A new and improved vehicle for delivering pharmaceutical ingredients to the human skin in a manner whereby the bioavailability, subcutaneous adsorption, and effectiveness of the active ingredient are remarkably enhanced. The vehicle comprises a volatile silicone, a fatty alcohol having from 12-22 carbon atoms, a preselected active ingredient; and such preservatives or emulsifying agents as may be warranted.
Inventors
- 👤 Richard A. Scott
- 👤 Mitchell S. Wortzman
- 👤 Eric Jungermann
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 19:45
CPC Classifications
A; A61; A61Q; A61Q19/00; A61Q19/007; A61K; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K47/24; A61K8/00; A61K8/02; A61K8/0216; A61K8/0229; A61K8/18; A61K8/30; A61K8/33; A61K8/34; A61K8/342; A61K8/347; A61K8/38; A61K8/58; A61K8/585; A61K8/63; A61K8/67; A61K8/671; A61K9/00; A61K9/0012; A61K9/0014; A61Q17/00; A61Q17/02; A61Q19/02; Y; Y10; Y10S; Y10S424/00; Y10S424/05; Y10S424/10
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
74 words
A pharmaceutical preparation having enhanced bioavailability and percutaneous adsorption comprising a mixture containing from about 20% up to about 40% (w/w) fatty alcohol having 12 to 22 carbon atoms or mixtures thereof; from about 30% up to about 60% (w/w) of a volatile silicone; from about 0.1% up to about 10% (w/w) of hydroquinone and from about 1% to about 10% of an ingredient selected from a preservative, an emulsifier or a mixture thereof.
Claim 2
Dependent Claim
74 words
A pharmaceutical preparation having enhanced bioavailability and percutaneous adsorption comprising a mixture containing from about 20% up to about 40% (w/w) fatty alcohol having 12 to 22 carbon atoms or mixtures thereof; from about 30% up to about 60% (w/w) of a volatile silicone; from about 0.1% up to about 10% (w/w) of hydroquinone and from about 1% to about 10% of an ingredient selected from a preservative, an emulsifier or a mixture thereof.
Claim 3
Dependent Claim
19 words
A system according to claim 1 in which said fatty alcohol comprises a mixture of stearyl and cetyl alcohol.
Claim 4
Dependent Claim
13 words
A system according to claim 1 in which said volatile silicone is cyclomethicone.
Claim 5
Dependent Claim
13 words
A system according to claim 1 in which said volatile silicone is dimethicone.
Claim 6
Dependent Claim
19 words
A system according to claim 3 in which said fatty alcohol comprises a mixture of stearyl and cetyl alcohol.
Claim 7
Dependent Claim
19 words
A system according to claim 4 in which said fatty alcohol comprises a mixture of stearyl and cetyl alcohol.
Claim 8
Dependent Claim
77 words
A pharmaceutical preparation for the treatment of hyperpigmentation consisting of from about 0.1% up to about 10% (w/w) of hydroquinone as its essential ingredient, said ingredient dispersed throughout a semi-solid vehicle having from about 20% up to about 40% (w/w) stearyl and cetyl alcohol; from about 30% up to about 60% (w/w) of a volatile silicone; and from about 1% to about 10% w/w of an ingredient selected from a preservative, an emulsifier or a mixture thereof.
Claim 9
Dependent Claim
77 words
A pharmaceutical preparation for the treatment of hyperpigmentation consisting of from about 0.1% up to about 10% (w/w) of hydroquinone as its essential ingredient, said ingredient dispersed throughout a semi-solid vehicle having from about 20% up to about 40% (w/w) stearyl and cetyl alcohol; from about 30% up to about 60% (w/w) of a volatile silicone; and from about 1% to about 10% w/w of an ingredient selected from a preservative, an emulsifier or a mixture thereof.
Claim 10
Dependent Claim
14 words
A pharmaceutical preparation according to claim 7 in which said volatile silicone is cyclomethicone.
References Cited (Backward Citations)
GB803289A
Cited
GB1206790A
Cited
US4264586A
Cited
US4280994A
Cited
US4122029A
Cited
US4265878A
Cited
US4355046A
Cited
US4435382A
Cited
US4421769A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-07-06 | 1991-01-05 | 1991-07-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-07-06 | 1995-01-05 | 1995-07-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-07-06 | 1999-01-05 | 1999-07-07 | $7700.00 | Window Closed / Lapsed |